Objectives and endpoints
PD, SD
DISEASE
The primary objective was to evaluate the safety profile and determine the MTD/RP2D and schedule of AZD2811 by assessing the incidence of DLTs, AEs, and abnormal laboratory test results. Secondary objectives were evaluation of PK parameters and preliminary assessment of antitumour activity, including objective response rate (ORR [complete response + partial response (CR + PR)]) based on RECIST v1.1, and incidence of best overall response, stable disease (SD) and progressive disease (PD).